Secukinumab showed a favorable safety profile across age and bodyweight subgroups of pediatric patients with moderate to severe or severe chronic plaque psoriasis up to week 52. |
The safety of secukinumab was comparable with that of placebo, with no major differences in the adverse event profile between the low-dose and high-dose secukinumab groups. |
No new or unexpected safety signals were reported in the pediatric population treated with secukinumab, and the proportion of patients with infections was similar between age and bodyweight subgroups. The overall safety profile of secukinumab-treated pediatric patients was consistent with its known profile in the adult population. |
1 Introduction
2 Methods
2.1 Study Design and Patients
2.2 Objectives and Outcomes
Variable | Subgroups | A2311 study | A2310 study | ||
---|---|---|---|---|---|
LD | HD | LD | HD | ||
Age | < 12 years | 17 | 16 | 8 | 9 |
≥ 12 years | 25 | 26 | 32 | 31 | |
Bodyweight | < 25 kg | 8 | 5 | ||
25 to < 50 kg | 13 | 12 | 17 | 15 | |
≥ 50 kg | 25 | 26 | 22 | 21 |
2.3 Statistical Analyses
3 Results
3.1 Demographic and Baseline Disease Characteristics
Characteristics | SEC LD | SEC HD | Any SEC | PBO | ETN |
---|---|---|---|---|---|
N = 82 | N = 82 | N = 164 | N = 41 | N = 41 | |
Age, years, mean ± SD | 13.1 ± 3.22 | 13.0 ± 3.31 | 13.0 ± 3.25 | 13.7 ± 3.27 | 13.5 ± 2.94 |
6–12 years, n (%) | 25 (30.5) | 25 (30.5) | 50 (30.5) | 10 (24.4) | 10 (24.4) |
12–18 years, n (%) | 57 (69.5) | 57 (69.5) | 114 (69.5) | 31 (75.6) | 31 (75.6) |
Female, n (%) | 47 (57.3) | 48 (58.5) | 95 (57.9) | 22 (53.7) | 25 (61.0) |
Bodyweight, kg, mean ± SD | 53.5 ± 17.59 | 54.7 ± 19.62 | 54.1 ± 18.58 | 55.7 ± 22.28 | 52.0 ± 19.43 |
< 25 kg, n (%) | 6 (7.3) | 7 (8.5) | 13 (7.9) | 3 (7.3) | 4 (9.8) |
25 to < 50 kg, n (%) | 30 (36.6) | 27 (32.9) | 57 (34.8) | 17 (41.5) | 16 (39.0) |
≥ 50 kg, n (%) | 46 (56.1) | 48 (58.5) | 94 (57.3) | 21 (51.2) | 21 (51.2) |
Caucasian, n (%) | 73 (89.0) | 72 (87.8) | 145 (88.4) | 36 (87.8) | 30 (73.2) |
BMI (kg/m2), mean ± SD | 21.0 ± 4.50 | 21.7 ± 4.42 | 21.3 ± 4.46 | 22.2 ± 6.20 | 21.0 ± 4.80 |
Baseline PASI score, mean ± SD | 22.9 ± 7.60 | 23.5 ± 8.85 | 23.2 ± 8.22 | 28.0 ± 8.09 | 28.4 ± 9.06 |
PASI score ≤ 20, n (%) | 27 (32.9) | 25 (30.5) | 52 (31.7) | 0 (0.0) | 0 (0.0) |
PASI score > 20, n (%) | 55 (67.1) | 57 (69.5) | 112 (68.3) | 41 (100.0) | 41 (100.0) |
Baseline total BSA, mean ± SD | 33.4 ± 13.18 | 35.2 ± 17.77 | 34.3 ± 15.62 | 39.0 ± 17.6 | 43.1 ± 19.56 |
Baseline IGA mod 2011 score, n (%) | |||||
3 (moderate disease) | 29 (35.4) | 30 (36.6) | 59 (36.0) | 0 (0.0) | 0 (0.0) |
4 (severe disease) | 53 (64.6) | 52 (63.4) | 105 (64.0) | 41 (100.0) | 41 (100.0) |
Severity of psoriasisa, n (%) | |||||
Moderate | 30 (36.6) | 34 (41.5) | 64 (39.0) | 0 (0.0) | 0 (0.0) |
Severe | 52 (63.4) | 48 (58.5) | 100 (61.0) | 41 (100.0) | 41 (100.0) |
Time since first diagnosis of plaque-type psoriasis, years, mean ± SD | 4.4 ± 3.98 | 4.7 ± 4.27 | 4.5 ± 4.12 | 6.0 ± 5.09 | 4.6 ± 3.73 |
Previous biologic psoriasis therapy, n (%) | 9 (11.0) | 6 (7.3) | 15 (9.1) | 0 (0.0) | 1 (2.4) |
Previous systemic psoriasis therapy, n (%) | 43 (52.4) | 39 (47.6) | 82 (50.0) | 20 (48.8) | 19 (46.3) |
Psoriatic arthritis history, n (%) | 6 (7.3) | 3 (3.7) | 9 (5.5) | 3 (7.3) | 3 (7.3) |
Obesity history, n (%) | 3 (3.7) | 3 (3.7) | 6 (3.7) | 1 (2.4) | 1 (2.4) |
3.2 Overall Safety Findings
Pediatric population: EAIR/100 patient-years (95% CI) | Adult population: EAIR/100 patient-years (95% CI) | |||||||
---|---|---|---|---|---|---|---|---|
Any SEC LD N = 98 | Any SEC HD N = 100 | Any SEC N = 198 | ETN N = 41 | Any SEC 150 mg N = 999 | Any SEC 300 mg N = 990 | Any SEC N = 1989 | ETN N = 323 | |
Total AEs | 190.5 (149.3, 239.5) | 207.7 (163.1, 260.8) | 198.8 (167.9, 233.6) | 266.3 (184.4, 372.2) | 255.5 (238.1, 273.9) | 256.6 (239.2, 274.9) | 256.1 (243.7, 268.9) | 248.0 (218.5, 280.4) |
SAEs | 7.8 (3.1, 16.1) | 6.7 (2.5, 14.6) | 7.3 (3.9, 12.4) | 14.5 (4.7, 33.9) | 7.5 (5.8, 9.6) | 7.5 (5.8, 9.6) | 7.5 (6.3, 9.0) | 6.9 (4.2, 10.7) |
Discontinued study treatment due to any AE | 2.2 (0.3, 7.8) | 3.3 (0.7, 9.6) | 2.7 (0.9, 6.4) | 2.7 (0.1, 14.8) | 3.6 (2.4, 5.1) | 3.4 (2.3, 4.9) | 3.5 (2.7, 4.5) | 4.1 (2.1, 7.1) |
Most frequent AEs (by SOC)a | ||||||||
Infections and infestation | 107.2 (81.4, 138.5) | 110.6 (83.8, 143.3) | 108.8 (89.9, 130.6) | 125.8 (82.9, 183.0) | 98.1 (90.0, 106.8) | 104.5 (96.1, 113.5) | 101.3 (95.4, 107.5) | 92.0 (78.7, 106.8) |
Skin and subcutaneous tissue disorders | 29.5 (18.7, 44.2) | 26.2 (16.2, 40.1) | 27.8 (20.2, 37.3) | 30.0 (14.4, 55.1) | 26.7 (23.2, 30.7) | 28.9 (25.2, 33.1) | 27.8 (25.2, 30.6) | 24.3 (18.6, 31.1) |
Gastrointestinal disorders | 22.2 (13.2, 35.1) | 32.9 (21.3, 48.6) | 27.4 (19.8, 36.9) | 49.6 (27.1, 83.2) | 28.7 (25.0, 32.8) | 28.7 (25.0, 32.9) | 28.7 (26.1, 31.6) | 26.9 (20.9, 34.1) |
General disorders and administration-site conditions | 15.5 (8.3, 26.6) | 18.7 (10.4, 30.8) | 17.1 (11.3, 24.7) | 25.1 (10.8, 49.4) | 15.4 (12.8, 18.4) | 16.5 (13.8, 19.6) | 16.0 (14.1, 18.0) | 33.0 (26.1, 41.1) |
Respiratory, thoracic, and mediastinal disorders | 11.5 (5.5, 21.2) | 19.1 (10.9, 31.1) | 15.3 (10.0, 22.4) | 11.1 (3.0, 28.4) | 15.0 (12.5, 18.0) | 21.5 (18.4, 25.0) | 18.2 (16.2, 20.5) | 12.7 (8.9, 17.7) |
Most frequent AEs (by PT)a | ||||||||
Nasopharyngitis | 29.6 (18.8, 44.5) | 34.8 (22.8, 51.0) | 32.2 (23.8, 42.5) | 33.3 (16.6, 59.6) | 29.2 (25.4, 33.3) | 30.0 (26.2, 34.2) | 29.6 (26.9, 32.5) | 36.0 (28.8, 44.4) |
Headache | 11.4 (5.5, 21.0) | 11.6 (5.6, 21.4) | 11.5 (7.0, 17.8) | 11.2 (3.0, 28.6) | 10.3 (8.2, 12.7) | 12.6 (10.3, 15.3) | 11.5 (9.9, 13.2) | 15.0 (10.7, 20.4) |
Pharyngitis | 9.0 (3.9, 17.7) | 8.1 (3.3, 16.7) | 8.6 (4.8, 14.1) | 8.2 (1.7, 24.0) | 2.8 (1.8, 4.2) | 2.9 (1.9, 4.3) | 2.8 (2.1, 3.8) | 2.0 (0.8, 4.5) |
URTI | 6.7 (2.5, 14.6) | 5.6 (1.8, 13.1) | 6.2 (3.1, 11.0) | 8.4 (1.7, 24.7) | 9.9 (7.9, 12.3) | 8.3 (6.5, 10.5) | 9.1 (7.7, 10.7) | 6.3 (3.7, 9.9) |
Acne | 9.1 (3.9, 17.9) | 3.3 (0.7, 9.7) | 6.2 (3.1, 11.0) | 0.0 (0.0, 9.7) | 0.5 (0.1, 1.2) | 1.1 (0.6, 2.1) | 0.8 (0.4, 1.3) | 1.0 (0.2, 3.0) |
Diarrhea | 4.5 (1.2, 11.4) | 7.9 (3.2, 16.3) | 6.2 (3.1, 11.1) | 2.7 (0.1, 15.0) | 6.5 (4.9, 8.5) | 7.6 (5.8, 9.7) | 7.1 (5.8, 8.4) | 7.8 (4.9, 11.8) |
AEs of special interesta | ||||||||
Hypersensitivity (SMQ) (narrow) | 8.0 (3.2, 16.4) | 14.2 (7.3, 24.8) | 11.0 (6.6, 17.2) | 14.5 (4.7, 33.9) | 11.2 (9.0, 13.8) | 11.8 (9.6, 14.4) | 11.5 (9.9, 13.3) | 11.2 (7.6, 15.9) |
Neutropenia (NMQ) (narrow) | 5.6 (1.8, 13.2) | 3.3 (0.7, 9.7) | 4.5 (1.9, 8.8) | 2.7 (0.1, 14.9) | 1.3 (0.6, 2.3) | 1.3 (0.6, 2.3) | 1.3 (0.8, 1.9) | 1.7 (0.6, 4.0) |
Neutropenia (PT) | 4.5 (1.2, 11.4) | 2.2 (0.3, 7.9) | 3.3 (1.2, 7.2) | 2.7 (0.1, 14.9) | 0.7 (0.3, 1.5) | 0.7 (0.3, 1.5) | 0.7 (0.4, 1.2) | 1.4 (0.4, 3.5) |
Candida infections (HLT) | 2.2 (0.3, 7.9) | 2.2 (0.3, 8.0) | 2.2 (0.6, 5.6) | 0.0 (0.0, 9.7) | 2.2 (1.3, 3.4) | 4.2 (2.9, 5.8) | 3.2 (2.4, 4.2) | 1.4 (0.4, 3.5) |
Vulvovaginal candidiasis (PT) | 1.1 (0.0, 6.1) | 1.1 (0.0, 6.1) | 1.1 (0.1, 3.9) | 0.0 (0.0, 9.7) | 0.6 (0.2, 1.3) | 0.8 (0.3, 1.7) | 0.7 (0.4, 1.2) | 0.0 (0.0, 1.2) |
Nail Candida (PT) | 0.0 (0.0, 4.0) | 1.1 (0.0, 6.1) | 0.5 (0.0, 3.0) | 0.0 (0.0, 9.7) | 0.0 (0.0, 0.4) | 0.0 (0.0, 0.4) | 0.0 (0.0, 0.2) | 0.0 (0.0, 1.2) |
Skin Candida (PT) | 1.1 (0.0, 6.0) | 0.0 (0.0, 4.0) | 0.5 (0.0, 3.0) | 0.0 (0.0, 9.7) | 0.5 (0.1, 1.2) | 0.2 (0.0, 0.8) | 0.3 (0.1, 0.7) | 0.7 (0.1, 2.4) |
Suicide/self-injury (SMQ) | 2.2 (0.3, 7.8) | 0.0 (0.0, 4.0) | 1.1 (0.1, 3.9) | 0.0 (0.0, 9.7) | 0.2 (0.0, 0.8) | 0.0 (0.0, 0.4) | 0.1 (0.0, 0.4) | 0.0 (0.0, 1.2) |
Intentional self-injury (PT) | 1.1 (0.0, 6.0) | 0.0 (0.0, 4.0) | 0.5 (0.0, 3.0) | 0.0 (0.0, 9.7) | 0.0 (0.0, 0.4) | 0.0 (0.0, 0.4) | 0.0 (0.0, 0.2) | 0.0 (0.0, 1.2) |
Suicidal ideation (PT) | 1.1 (0.0, 6.0) | 0.0 (0.0, 4.0) | 0.5 (0.0, 3.0) | 0.0 (0.0, 9.7) | 0.0 (0.0, 0.4) | 0.0 (0.0, 0.4) | 0.0 (0.0, 0.2) | 0.0 (0.0, 1.2) |
Suicide attempt (PT) | 0.0 (0.0, 4.0) | 0.0 (0.0, 4.0) | 0.0 (0.0, 2.0) | 0.0 (0.0, 9.7) | 0.1 (0.0, 0.6) | 0.0 (0.0, 0.4) | 0.1 (0.0, 0.3) | 0.0 (0.0, 1.2) |
IBDb (NMQ) (narrow) | 0.0 (0.0, 4.0) | 1.1 (0.0, 6.1) | 0.5 (0.0, 3.0) | 0.0 (0.0, 9.7) | 0.3 (0.1, 1.0) | 0.5 (0.1, 1.2) | 0.4 (0.2, 0.8) | 0.3 (0.0, 1.9) |
MACE (MI, Stroke, CV death) (NMQ) | 0.0 (0.0, 4.0) | 0.0 (0.0, 4.0) | 0.0 (0.0, 2.0) | 0.0 (0.0, 9.7) | 0.7 (0.3, 1.5) | 0.5 (0.1, 1.2) | 0.6 (0.3, 1.1) | 0.3 (0.0, 1.9) |
Malignant or unspecified tumors (SMQ) | 0.0 (0.0, 4.0) | 0.0 (0.0, 4.0) | (0.0 (0.0, 2.0) | 0.0 (0.0, 9.7) | 1.1 (0.6, 2.1) | 0.8 (0.3, 1.7) | 1.0 (0.6, 1.6) | 0.7 (0.1, 2.4) |
ISRsc | 4.5 (1.2, 11.5) | 4.4 (1.2, 11.4) | 4.5 (1.9, 8.8) | 11.5 (3.1, 29.4) | 1.6 (0.9, 2.7) | 1.8 (1.1, 3.0) | 1.7 (1.2, 2.5) | 13.0 (9.1, 18.1) |
3.3 Safety: Subgroup Analysis of the Pediatric Pool by Age and Bodyweight
3.3.1 Safety Analysis by Age Subgroup in the Pediatric Pool
(i) Age group: <12 years | EAIR/100 patient-years (95% CI) | |||
---|---|---|---|---|
SEC LD N = 30 | SEC HD N = 28 | Any SEC N = 58 | ETN N = 10 | |
Total AEs | 152.8 (94.6, 233.6) | 185.7 (115.0, 283.9) | 167.7 (120.8, 226.6) | 212.0 (85.2, 436.8) |
SAEs | 3.5 (0.1, 19.5) | 12.2 (2.5, 35.7) | 7.5 (2.1, 19.3) | 11.6 (0.3, 64.5) |
Treatment discontinuation due to AEs | 0.0 (0.0, 12.8) | 7.9 (1.0, 28.4) | 3.7 (0.4, 13.3) | 0.0 (0.0, 38.9) |
Top five most frequent AEs (by SOC)a | ||||
Infections and infestations | 63.9 (34.1, 109.4) | 121.9 (72.3, 192.7) | 88.3 (60.0, 125.4) | 82.4 (26.8, 192.4) |
Gastrointestinal disorders | 20.1 (6.5, 46.9) | 22.6 (7.3, 52.8) | 21.3 (10.2, 39.2) | 26.2 (3.2, 94.6) |
Skin and subcutaneous tissue disorders | 19.3 (6.3, 45.0) | 16.2 (4.4, 41.4) | 17.8 (8.1, 33.7) | 24.8 (3.0, 89.5) |
Blood and lymphatic system disorders | 11.2 (2.3, 32.8) | 17.5 (4.8, 44.7) | 14.1 (5.7, 29.1) | 0.0 (0.0, 38.9) |
Respiratory, thoracic, and mediastinal disorders | 7.3 (0.9, 26.3) | 17.1 (4.7, 43.7) | 11.8 (4.3, 25.7) | 0.0 (0.0, 38.9) |
Top five most frequent AEs (by PT)a | ||||
Nasopharyngitis | 11.1 (2.3, 32.6) | 12.5 (2.6, 36.5) | 11.8 (4.3, 25.6) | 24.5 (3.0, 88.6) |
Abdominal pain | 7.5 (0.9, 27.0) | 8.4 (1.0, 30.3) | 7.9 (2.2, 20.2) | 11.6 (0.3, 64.5) |
Viral upper respiratory tract infection | 3.6 (0.1, 19.9) | 12.5 (2.6, 36.6) | 7.7 (2.1, 19.7) | 11.4 (0.3, 63.7) |
Cough | 3.6 (0.1, 19.9) | 8.0 (1.0, 29.0) | 5.7 (1.2, 16.6) | 0.0 (0.0, 38.9) |
Diarrhea | 3.6 (0.1, 20.1) | 8.2 (1.0, 29.5) | 5.7 (1.2, 16.8) | 0.0 (0.0, 38.9) |
AEs of special interest | ||||
Hypersensitivity (SMQ) (narrow) | 3.5 (0.1, 19.7) | 8.0 (1.0, 29.0) | 5.6 (1.2, 16.5) | 44.6 (9.2, 130.3) |
Infections and infestations (SOC) | 63.9 (34.1, 109.4) | 121.9 (72.3, 192.7) | 88.3 (60.0, 125.4) | 82.4 (26.8, 192.4) |
Neutropenia (NMQ) (narrow) | 11.2 (2.3, 32.8) | 8.2 (1.0, 29.6) | 9.8 (3.2, 22.8) | 0.0 (0.0, 38.9) |
ISRs | 7.4 (0.9, 26.7) | 0.0 (0.0, 14.3) | 3.8 (0.5, 13.7) | 11.8 (0.3, 65.5) |
(ii) Age group: ≥12 years | EAIR/100 patient-years (95% CI) | |||
---|---|---|---|---|
SEC LD N = 68 | SEC HD N = 72 | Any SEC N = 140 | ETN N = 31 | |
Total AEs | 211.5 (157.9, 277.3) | 217.9 (163.2, 285.1) | 214.7 (175.6, 259.9) | 285.3 (188.0, 415.1) |
SAEs | 9.8 (3.6, 21.4) | 4.6 (1.0, 13.5) | 7.1 (3.3, 13.5) | 15.5 (4.2, 39.7) |
Treatment discontinuation due to AEs | 3.2 (0.4, 11.4) | 1.5 (0.0, 8.4) | 2.3 (0.5, 6.8) | 3.6 (0.1, 19.8) |
Top five most frequent AEs (by SOC)a | ||||
Infections and infestations | 133.2 (97.1, 178.2) | 106.1 (75.4, 145.0) | 119.0 (94.9, 147.4) | 142.9 (89.5, 216.3) |
Skin and subcutaneous tissue disorders | 34.5 (20.4, 54.5) | 30.7 (17.9, 49.2) | 32.6 (22.7, 45.3) | 31.6 (13.7, 62.3) |
Gastrointestinal disorders | 23.1 (12.3, 39.6) | 37.2 (22.7, 57.4) | 30.0 (20.7, 42.1) | 58.2 (30.1, 101.7) |
General disorders and administration-site conditions | 13.5 (5.8, 26.7) | 27.5 (15.4, 45.4) | 20.2 (12.8, 30.4) | 24.7 (9.1, 53.8) |
Nervous system disorders | 20.7 (10.7, 36.2) | 16.6 (8.0, 30.6) | 18.6 (11.7, 28.2) | 15.2 (4.1, 38.8) |
Top five most frequent AEs (by PT)a | ||||
Nasopharyngitis | 39.5 (24.1, 60.9) | 45.4 (28.8, 68.1) | 42.4 (30.7, 57.2) | 36.2 (16.5, 68.6) |
Headache | 17.0 (8.2, 31.3) | 16.6 (8.0, 30.6) | 16.8 (10.3, 26.0) | 15.2 (4.1, 38.8) |
Pharyngitis | 11.5 (4.6, 23.7) | 9.7 (3.6, 21.2) | 10.6 (5.6, 18.1) | 11.1 (2.3, 32.3) |
Acne | 11.6 (4.7, 23.9) | 4.6 (1.0, 13.6) | 8.0 (3.8, 14.7) | 0.0 (0.0, 12.9) |
Oropharyngeal pain | 4.8 (1.0, 14.2) | 11.1 (4.5, 23.0) | 8.0 (3.8, 14.7) | 3.6 (0.1, 20.1) |
AEs of special interest | ||||
Hypersensitivity (SMQ) (narrow) | 10.1 (3.7, 21.9) | 16.8 (8.1, 30.9) | 13.4 (7.7, 21.8) | 7.2 (0.9, 26.1) |
Infections and infestations (SOC) | 133.3 (97.3, 178.4) | 110.2 (78.7, 150.0) | 121.3 (96.9, 150.0) | 142.9 (89.5, 216.3) |
Neutropenia (NMQ) (narrow) | 3.2 (0.4, 11.7) | 1.5 (0.0, 8.5) | 2.4 (0.5, 6.9) | 3.6 (0.1, 19.9) |
ISRs | 3.2 (0.4, 11.7) | 6.2 (1.7, 16.0) | 4.8 (1.7, 10.4) | 11.4 (2.3, 33.2) |
3.3.2 Safety Analysis by Bodyweight Subgroup in the Pediatric Pool
(i) Bodyweight group: < 25 kg | EAIR/100 patient-years (95% CI) | |||
---|---|---|---|---|
SEC LD N = 8 | SEC HD N = 8 | Any SEC N = 16 | ETN N = 4 | |
Total AEs | 116.3 (37.8, 271.5) | 283.5 (114.0, 584.0) | 177.3 (91.6, 309.7) | 92.6 (11.2, 334.5) |
SAEs | 13.6 (0.3, 75.8) | 14.3 (0.4, 79.5) | 13.9 (1.7, 50.3) | 0.0 (0.0, 92.4) |
Treatment discontinuation due to AEs | None | None | None | None |
Most frequent AEs (by SOC)a | ||||
Infections and infestations | 34.2 (4.1, 123.6) | 141.6 (52.0, 308.1) | 79.3 (34.3, 156.3) | 30.6 (0.8, 170.3) |
Blood and lymphatic system disorders | 32.5 (3.9, 117.4) | 55.0 (11.3, 160.7) | 43.1 (14.0, 100.5) | 0.0 (0.0, 92.4) |
Cardiac disorders | 14.8 (0.4, 82.4) | 14.3 (0.4, 79.6) | 14.5 (1.8, 52.5) | 0.0 (0.0, 92.4) |
Skin and subcutaneous tissue disorders | 0.0 (0.0, 49.0) | 26.9 (3.3, 97.3) | 13.4 (1.6, 48.3) | 0.0 (0.0, 92.4) |
Eye disorders | 0.0 (0.0, 49.0) | 14.7 (0.4, 82.0) | 7.0 (0.2, 38.9) | 0.0 (0.0, 92.4) |
Most frequent AEs (by PT)a | ||||
Nasopharyngitis | 15.2 (0.4, 84.8) | 30.3 (3.7, 109.4) | 22.8 (4.7, 66.5) | 0.0 (0.0, 92.4) |
Leukopenia | 15.0 (0.4, 83.3) | 14.4 (0.4, 80.5) | 14.7 (1.8, 53.1) | 0.0 (0.0, 92.4) |
Pharyngotonsillitis | 14.7 (0.4, 81.9) | 13.2 (0.3, 73.8) | 13.9 (1.7, 50.3) | 0.0 (0.0, 92.4) |
Viral upper respiratory tract infection | 0.0 (0.0, 49.0) | 29.1 (3.5, 105.0) | 13.9 (1.7, 50.2) | 30.6 (0.8, 170.3) |
Influenza | 13.4 (0.3, 74.5) | 13.0 (0.3, 72.5) | 13.2 (1.6, 47.7) | 0.0 (0.0, 92.4) |
AEs of special interest | ||||
Hypersensitivity (SMQ) (narrow) | 0.0 (0.0, 49.0) | 13.3 (0.3, 74.0) | 6.6 (0.2, 37.0) | 0.0 (0.0, 92.4) |
Infections and infestations (SOC) | 34.2 (4.1, 123.6) | 141.6 (52.0, 308.1) | 79.3 (34.3, 156.3) | 30.6 (0.8, 170.3) |
Neutropenia (NMQ) (narrow) | 32.5 (3.9, 117.4) | 14.4 (0.4, 80.5) | 22.9 (4.7, 67.0) | 0.0 (0.0, 92.4) |
ISRs | 0.0 (0.0, 49.0) | 0.0 (0.0, 47.5) | 0.0 (0.0, 24.1) | 33.1 (0.8, 184.5) |
(ii) Bodyweight group: ≥ 25 kg and < 50 kg | EAIR/100 patient-years (95% CI) | |||
---|---|---|---|---|
SEC LD N = 37 | SEC HD N = 34 | Any SEC N = 71 | ETN N = 16 | |
Total AEs | 185.5 (123.3, 268.2) | 200.9 (130.0, 296.5) | 192.5 (144.2, 251.8) | 319.6 (174.7, 536.2) |
SAEs | 2.9 (0.1, 16.0) | 6.9 (0.8, 25.0) | 4.7 (1.0, 13.7) | 15.6 (1.9, 56.5) |
Treatment discontinuation due to AEs | 2.9 (0.1, 16.0) | 6.9 (0.8, 24.9) | 4.7 (1.0, 13.7) | 0.0 (0.0, 25.6) |
Most frequent AEs (by SOC)a | ||||
Infections and infestations | 98.9 (62.0, 149.8) | 91.0 (53.0, 145.7) | 95.3 (67.8, 130.3) | 141.4 (70.6, 253.0) |
Gastrointestinal disorders | 35.2 (16.9, 64.7) | 32.3 (13.9, 63.7) | 33.8 (20.1, 53.5) | 46.8 (15.2, 109.1) |
General disorders and administration-site conditions | 27.9 (12.1, 55.1) | 19.0 (6.2, 44.3) | 23.7 (12.6, 40.5) | 34.1 (9.3, 87.2) |
Skin and subcutaneous tissue disorders | 26.8 (11.6, 52.9) | 18.5 (6.0, 43.2) | 22.9 (12.2, 39.1) | 51.9 (19.1, 113.0) |
Respiratory, thoracic, and mediastinal disorders | 9.0 (1.9, 26.4) | 22.4 (8.2, 48.7) | 15.0 (6.9, 28.4) | 15.3 (1.9, 55.3) |
Most frequent AEs (by PT)a | ||||
Nasopharyngitis | 15.5 (5.0, 36.2) | 23.5 (8.6, 51.2) | 19.0 (9.5, 34.1) | 23.1 (4.8, 67.6) |
Abdominal pain | 9.1 (1.9, 26.6) | 15.1 (4.1, 38.6) | 11.8 (4.7, 24.3) | 15.8 (1.9, 57.2) |
Cough | 5.9 (0.7, 21.4) | 14.5 (4.0, 37.1) | 9.8 (3.6, 21.3) | 7.2 (0.2, 39.9) |
Eosinophilia | 12.1 (3.3, 31.1) | 3.4 (0.1, 19.2) | 8.1 (2.6, 18.8) | 0.0 (0.0, 25.6) |
Headache | 0.0 (0.0, 10.5) | 18.6 (6.0, 43.3) | 8.1 (2.6, 18.8) | 15.4 (1.9, 55.7) |
AEs of special interest | ||||
Hypersensitivity (SMQ) (narrow) | 6.0 (0.7, 21.5) | 19.3 (6.3, 45.0) | 11.8 (4.7, 24.2) | 25.8 (5.3, 75.3) |
Infections and infestations (SOC) | 98.9 (62.0, 149.8) | 91.0 (53.0, 145.7) | 95.3 (67.8, 130.3) | 141.4 (70.6, 253.0) |
Neutropenia (NMQ) (narrow) | 2.9 (0.1, 16.2) | 3.5 (0.1, 19.3) | 3.2 (0.4, 11.4) | 0.0 (0.0, 25.6) |
ISRs | 9.3 (1.9, 27.0) | 7.0 (0.8, 25.2) | 8.2 (2.7, 19.1) | 15.2 (1.8, 54.9) |
(iii) Bodyweight group: ≥ 50 kg | EAIR/100 patient-years (95% CI) | |||
---|---|---|---|---|
SEC LD N = 53 | SEC HD N = 58 | Any SEC N = 111 | ETN N = 21 | |
Total AEs | 211.2 (150.9, 287.6) | 202.8 (146.1, 274.1) | 206.8 (164.5, 256.7) | 289.1 (171.3, 456.9) |
SAEs | 10.6 (3.4, 24.6) | 5.6 (1.2, 16.3) | 7.9 (3.4, 15.6) | 17.0 (3.5, 49.6) |
Treatment discontinuation due to AEs | 2.0 (0.1, 11.2) | 1.8 (0.0, 10.2) | 1.9 (0.2, 6.9) | 5.2 (0.1, 29.0) |
Most frequent AEs (by SOC)a | ||||
Infections and infestations | 130.6 (90.4, 182.4) | 118.8 (82.3, 166.0) | 124.4 (96.6, 157.7) | 144.1 (80.6, 237.6) |
Skin and subcutaneous tissue disorders | 36.8 (20.6, 60.7) | 30.7 (16.8, 51.5) | 33.6 (22.5, 48.2) | 22.4 (6.1, 57.5) |
Gastrointestinal disorders | 17.7 (7.7, 34.9) | 36.1 (20.6, 58.6) | 26.8 (17.2, 39.9) | 66.4 (30.4, 126.1) |
Nervous system disorders | 25.0 (12.5, 44.7) | 9.8 (3.2, 22.8) | 16.8 (9.6, 27.2) | 10.6 (1.3, 38.2) |
Respiratory, thoracic, and mediastinal disorders | 15.2 (6.1, 31.4) | 18.0 (8.2, 34.2) | 16.7 (9.5, 27.1) | 10.6 (1.3, 38.1) |
Most frequent AEs (by PT)a | ||||
Nasopharyngitis | 43.9 (25.5, 70.2) | 42.3 (25.1, 66.9) | 43.0 (30.0, 59.9) | 49.7 (21.5, 98.0) |
Headache | 22.3 (10.7, 40.9) | 9.8 (3.2, 22.8) | 15.6 (8.7, 25.7) | 10.6 (1.3, 38.2) |
Pharyngitis | 17.3 (7.5, 34.0) | 9.8 (3.2, 22.9) | 13.4 (7.1, 22.9) | 16.5 (3.4, 48.1) |
Oropharyngeal pain | 6.2 (1.3, 18.2) | 13.6 (5.5, 28.1) | 10.1 (4.8, 18.5) | 0.0 (0.0, 18.8) |
Rhinitis | 6.2 (1.3, 18.1) | 11.8 (4.3, 25.6) | 9.0 (4.1, 17.2) | 5.3 (0.1, 29.7) |
AEs of special interest | ||||
Hypersensitivity (SMQ) (narrow) | 10.7 (3.5, 25.0) | 11.8 (4.3, 25.6) | 11.3 (5.6, 20.1) | 10.6 (1.3, 38.4) |
Infections and infestations (SOC) | 130.8 (90.6, 182.8) | 124.3 (86.6, 172.8) | 127.4 (99.1, 161.2) | 144.1 (80.6, 237.6) |
Neutropenia (NMQ) (narrow) | 4.2 (0.5, 15.0) | 1.8 (0.0, 10.3) | 2.9 (0.6, 8.6) | 5.2 (0.1, 29.1) |
ISRs | 2.0 (0.1, 11.4) | 3.7 (0.5, 13.5) | 2.9 (0.6, 8.6) | 5.3 (0.1, 29.8) |